- Home
- / Aadi Bioscience
Aadi Bioscience
Revenue
$24.4 M
FY, 2023
Aadi Bioscience Summary
Company Summary
- Overview
- Aadi Bioscience is a biopharmaceutical company developing an albumin-bound mTOR inhibitor for targeted patient populations in oncology, cardiovascular, and CNS diseases. It offers ABI-009, a nanoparticle albumin-bound sirolimus (rapamycin), an active form of sirolimus complexed with albumin.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2011
- HQ
- Los Angeles, CA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
LocationsView all
1 location detected
Los Angeles, CA HQ
United States
17383 Sunset Blvd a250, Pacific Palisades
Aadi Bioscience Financials
Summary Financials
- Revenue (Q1, 2024)
- $5.4M
- Gross profit (Q1, 2024)
- $4.7M
- Net income (Q1, 2024)
- ($18.3M)
- Cash (Q1, 2024)
- $53.8M
- EBIT (Q1, 2024)
- ($19.5M)